Pilot Study of DRibble Vaccine for Prostate Cancer Patients

• Status: Completed
• Trial end date: 2018-08-15
• Target enrollment: 0
• Participant gender: Male

Summary

This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UbiVac
• Collaborators: Providence Cancer Center; Providence Cancer Center, Earle A. Chiles Research Institute; Providence Health & Services
• Treatments: Cyclophosphamide; Imiquimod; Vaccines

Criteria

Inclusion Criteria:

• Subjects have measurable or evaluable metastatic castrate resistant adenocarcinoma of the prostate with progression after chemotherapy, combined androgen blockade and/or peripheral androgen or androgen receptor suppression. Either histologic or serum marker diagnosis is acceptable.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• Ability to give informed consent and comply with the protocol.

• Prior therapy with investigational agents must have been completed at least 3 weeks prior to study enrollment.

• Patients must have normal organ and marrow function as determined by routine blood tests

Exclusion Criteria:

• Active autoimmune disease except vitiligo or hypothyroidism.

• Active other malignancy.

• Known HIV positive and/or Hepatitis B or C positive.

• Other medical or psychiatric conditions that in the opinion of the Principal Investigator would preclude safe participation in protocol.